Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
代謝手術或semaglutide在2型糖尿病患者中的血糖及體重影響。
Diabetes Obes Metab 2024-09-19
這項研究比較了semaglutide和代謝及減重手術(MBS)對2型糖尿病及肥胖患者的影響。研究分析了606名接受MBS的患者和997名接受semaglutide的患者,結果顯示兩者皆能改善體重和血糖控制,但MBS組在介入後2年內,糖化血紅蛋白顯著較低(42.3 vs. 50.7),且完全緩解的比例較高(63.0% vs. 13.9%)。此外,MBS組的體重減輕也更明顯(26.4% vs. 5.2%)。總體來看,MBS在體重和血糖控制上表現更佳。
相關文章PubMedDOI
Exploring the relationship between problematic eating behaviors and bipolar disorder: A study on candidates for bariatric surgery.
探討問題性飲食行為與雙相情緒障礙之間的關係:一項針對減重手術候選者的研究。
J Affect Disord 2024-09-18
Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
在印度次大陸的超重/肥胖2型糖尿病患者中,使用GLP-1受體激動劑與鈉-葡萄糖共轉運蛋白-2抑制劑聯合療法改善臨床結果的實證研究。
J Assoc Physicians India 2024-09-18
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.
抗糖尿病藥物 GLP-1RA 和 SGLT-2i 對呼吸系統功能的可能影響。
Endocrine 2024-09-17
Fibroblast Growth Factor 21 Improves Insulin Sensitivity by Modulating the Bile Acid-Gut Microbiota Axis in Type Ⅱ Diabetic Mice.
Fibroblast Growth Factor 21 透過調節膽汁酸-腸道微生物群軸改善 II 型糖尿病小鼠的胰島素敏感性。
Free Radic Biol Med 2024-09-17
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
GLP-1 受體激動劑在物質使用障礙中的潛在角色:隨機試驗的系統性回顧。
Drug Alcohol Depend 2024-09-17